ArticleBiochemistry2010
Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2.
Article in Biochemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Synthesis of biologically active Shiga toxins in cell-free systems.Scientific reports · 2024Article
- The diverse landscape of AB5-type toxins.Engineering microbiology · 2023Review
- Structural Diversities of Lectins Binding to the Glycosphingolipid Gb3.Frontiers in molecular biosciences · 2021Review
- Shiga toxin suppresses noncanonical inflammasome responses to cytosolic LPS.Science immunology · 2020Article
- Bimodal Response to Shiga Toxin 2 Subtypes Results from Relatively Weak Binding to the Target Cell.Infection and immunity · 2019Article
- Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding.Scientific reports · 2016Article
- AB5 Preassembly Is Not Required for Shiga Toxin Activity.Journal of bacteriology · 2016Article
- The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1.Infection and immunity · 2016Article
- Do the A subunits contribute to the differences in the toxicity of Shiga toxin 1 and Shiga toxin 2?Toxins · 2015Review
- Identification of a wide range of motifs inhibitory to shiga toxin by affinity-driven screening of customized divalent peptides synthesized on a membrane.Applied and environmental microbiology · 2015Article
- Glycan based detection and drug susceptibility of influenza virus.Analytical chemistry · 2014Article
- The crystal structure of shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor.The Journal of biological chemistry · 2014Article
- Glycolipid binding preferences of Shiga toxin variants.PloS one · 2014Article
- Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants.Infection and immunity · 2013Article
- Capture of uropathogenic E. coli by using synthetic glycan ligands specific for the pap-pilus.Chembiochem : a European journal of chemical biology · 2013Article
- Shiga toxin binding to glycolipids and glycans.PloS one · 2012Article
- Membrane interaction of Pasteurella multocida toxin involves sphingomyelin.The FEBS journal · 2011Article
- Shiga toxin subtypes display dramatic differences in potency.Infection and immunity · 2011Article
- Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide.Infection and immunity · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Protein-glycan interactions are typically very weak, and avid binding is achieved when proteins express multiple glycan binding sites. Shiga toxin (Stx) uses glycan receptors to enter cells. Stx has five identical binding subunits, each with three nonidentical glycan binding sites. Previous studies examined binding to biantennary glycans expressing Pk trisaccharide mimics immobilized on streptavidin, resulting in display of four trisaccharides per streptavidin face. Stx1 preferred the Pk trisaccharide of its native receptor, globotriaosylceramide (Gb3), while the more potent and clinically relevant variant, Stx2, preferred the Pk trisaccharide with the terminal galactose replaced with N-acetylgalactosamine (NHAc-Pk). In the present study, binding of Stxs to Pk analogues was examined using two experimental platforms, ELISA and surface plasmon resonance (SPR). ELISA was more sensitive than SPR. Sensitivity in the ELISA was due to high streptavidin density, suggesting that avid binding may require engagement of more than four trisaccharides. Selectivity for the Pk analogues was maintained in both experimental platforms. Glycan preference was mapped to binding site 2, since reciprocal mutation of a single amino acid (asparagine 32 of Stx1 B-subunit/serine 31 of Stx2 B-subunit) reversed binding preference. However, native Stx1 bound well to plates loaded with a 50:50 mixture of Pk-NHAc-Pk, while Stx2 bound less efficiently, suggesting that one of the Stx1 binding sites may only engage Pk, while another may tolerate either Pk or NHAc-Pk. Varying glycan structure and density across different in vitro binding platforms revealed important differences in receptor binding properties between Stx1 and Stx2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.